TGFB1 and Hepatic fibrosis: Mechanistically, increased ECM degradation by MMP-9, reduced HSC activation and TGF-β as well as a decreased expression of the myofibroblast marker α-SMA were observed upon administration of TPO in an CCl4-induced mouse model of liver fibrosis [76] and in an rat partial hepatectomy model [77,78].